Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Molecular and Clinical Oncology
Join Editorial Board Propose a Special Issue
Print ISSN: 2049-9450 Online ISSN: 2049-9469
Journal Cover
March-2018 Volume 8 Issue 3

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
March-2018 Volume 8 Issue 3

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia

  • Authors:
    • Carmelo Gurnari
    • Paola Panetta
    • Emiliano Fabiani
    • Anna Maria Nardone
    • Diana Postorivo
    • Giulia Falconi
    • Luca Franceschini
    • Manuela Rizzo
    • Vito Mario Rapisarda
    • Eleonora De Bellis
    • Francesco Lo‑Coco
    • Maria Teresa Voso
  • View Affiliations / Copyright

    Affiliations: Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy, Hematology Department, Tor Vergata University Hospital, Rome, Italy, Laboratory of Medical Genetics, Tor Vergata Clinic, Rome, Italy, Hematology Department, Tor Vergata University Hospital, Rome, Italy
  • Pages: 463-465
    |
    Published online on: December 29, 2017
       https://doi.org/10.3892/mco.2017.1543
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

The World Health Organization classifies atypical chronic myeloid leukemia (aCML) as a myeloproliferative/myelodisplastic hematological disorder. The primary manifestations are leukocytosis with disgranulopoiesis, absence of basophilia and/or monocytosis, splenomegaly and absence of Philadelphia chromosome or BCR/ABL fusion. Overall 50‑65% of patients demonstrate karyotypic abnormalities, although no specific cytogenetic alterations have been associated with this disease. X chromosome alterations have been rarely reported in myeloid malignancies. Although Isodicentric X, idic(X)(q13) is well known in females with myelodysplastic syndromes (MDS), little data are available on X isochromosome and its pathogenetic potential in these disorders. i(X)(p10) is observed in a variety of hematologic malignancies, both myeloid and lymphoid, as a unique abnormality, as well as part of a more complex karyotype, in females and less frequently in male patients. The present report describes the first patient with aCML, with documented isolated i(X)(p10), who developed a secondary acute myeloid leukemia (sAML).

Case report

A 66 year-old woman presented to the Emergency Room of Tor Vergata University Hospital with lower back pain. Her past medical history was negative. Blood counts (CBC) revealed leukocytosis (55 109/l; differential: 87% neutrophils, 5.4% lymphocytes, 6.8% monocytes) and anemia (10 gr/dl). Splenomegaly was present at physical examination (18 cm longitudinal diameter at the abdomen ultrasound). The peripheral blood smear showed presence of immature granulocytes (>10% promyelocytes, myelocytes and metamyelocytes) and 6% myeloblasts, in the absence of monocytosis.

Bone marrow (BM) smears and BM biopsy were hypercellular with left shift of the granulocyte maturation curve, less than 5% CD34+ blasts, dyserythropoiesis and presence of small hypolobated megakaryocytes. Molecular analysis for the BCR-ABL fusion gene (p210, p190, p230), as well as locus-specific FISH for t(9;22) were negative. The standard karyotype analysis gave the initial result of a Xq23 deletion. To better characterize the molecular lesion, array CGH, and a locus-specific FISH were performed, as well as mutation studies on the diagnostic BM sample (Fig. 1 and Table I). The only detectable clonality marker was a X isochromosome i(X)(p10) in 7 of the 15 metaphases analyzed. The diagnosis of aCML was made.

Figure 1.

(A) GTG-banded karyotype from cultured bone marrow of the patient showing a del(X)(q23) in ~47% (7/15) of the metaphases analyzed. (B) X chromosome Array-CGH (oligo 180K; Agilent Technologies, Santa Clara, CA, USA) profile showing one duplication of the short arm at Xp22.33q11.1 (blue bar), 62,2 Mb in size and one deletion of the long arm at Xq11.1q28 (red bar), 92,7 Mb in size. (C) FISH analysis, using subtelomeric probes (Abbott Molecular, Des Plaines, IL, USA) specific for chromosome Xpter and Xqter, showing and confirming an isochromosome Xp (red arrow).

Table I.

Somatic mutations studied on the diagnostic BM sample by Sanger sequencing.

Table I.

Somatic mutations studied on the diagnostic BM sample by Sanger sequencing.

Gene locusMutation status
IDH1 R132WT
IDH2 R140WT
IDH2 R172WT
DNMT3A R882WT
SRSF2 P95-96WT
SF3B1 exons 13–16WT
U2AF1WT
SETBP1WT
ASXL1Silent mutation S1253S; 3′UTR A/G, position Chr20:32437360
ETNK1 exon 3WT

[i] WT, wild-type.

The patient started 5-hydroxyurea (1 g per day), with modest control on leucocytosis. Five months after the primary diagnosis, the patient presented with left hypochondrium pain. A CT-scan was diagnostic for a spleen infarction, with intracapsular hematoma. Thus, she underwent urgent splenectomy. The hystopatological examination of the spleen showed 5% MPO+ and CD34+ cells with hematopoietic invasion.

Almost one year after the primary diagnosis, exacerbation of leukocytosis (≥100×109/l), anemia and thrombocytopenia were observed, and the patient became transfusion-dependent. The BM examination showed leukemic evolution of aCML, with the presence of giant myeloid granular blasts (30% M2 FAB subtype), erythroid dysplasia and absence of megakariocytes. Immunophenotyping confirmed the progression to sAML.

Cytogenetic and molecular studies for recurrent mutations confirmed i(X)(p10) as the sole abnormality.

Discussion

We report on a patient with aCML and a i(X)(p10) as the sole molecular abnormality. Little is known on the mechanism of isochromosome formation and its pathogenetic impact (1). Frequency varies in different cancers types, with the highest incidence in germ cell neoplasms (60%), and the lowest in chronic myeloproliferative disorders (2.3%) (1).

Isochromosomes could result from transverse, instead of longitudinal meiotic mis-division of the centromere; another mechanism could be chromatid exchange involving two homologous chromosomes. In both cases, it leads to loss and gain of genetic material, likely resulting in deletion of tumor suppressor genes and amplification of oncogenes (2).

Of note, in hematologic neoplasms isochromosome formation is more frequent in lymphoid disorders (three times as common), while in myeloid neoplasms the highest incidence is observed in CML (18%) (2). In particular, i(X)(p10) isochromosome has been described as the sole abnormality in 11 patients, mostly in myeloid neoplasms (4 MDS, 3 AML, 2 chronic myelomonocytic leukemia) while in lymphoid malignancies is usually part of a complex karyotype and seems to be a secondary event (3,4).

The pathogenetic importance of i(X)(p10) is underscored by its presence as the sole acquired abnormality in these disorders. Its formation leads to the loss of the long-arm and gain of short-arm of chromosome X, resulting in a state of genetic imbalance. Costitutional i(X)(p10) is incompatible with life (2). Since i(X)(p10) is found also in males with hematologic disorders, it may reasonably arise from the active X chromosome. Thus, its formation in females may randomly derive from both the active or inactive X chromosome (4).

To the best of our knowledge, this is the first case of i(X)(p10) in aCML. Werner-Favre et al described in 1985 a case of aCML carrying a structural rearrangement of X chromosome, del (X)(q23) (5). The cytogenetic distinction between del(Xq) and i(Xp) is known to be difficult due to the similarity of X p- and q-arm band pattern, extending from the centromere to band Xq24 (6). Thus, it is not clear whether the previosuly reported case could be a i(Xp), due to the lack of data from advanced cytogenetic techniques as locus-specific FISH and CGH-array, not available at that time (Fig. 1).

Deletion of the long arm of X chromosome has been reported as recurrent karyotypic abnormality in patients with AML or MDS as well as with solid tumors. Previously, two patients with AML and three with MDS, and del (X)(q23) had been described (7,8). In these cases, only conventional G-banding and dual-color FISH had been performed to rule out the presence of a iso-dicentric (X)(q13). Of note all these patients were females between 46 and 65 years old, with breakpoints regions apparently restricted to q13~q24. The median time to AML progression reported by Olshanskaya for MDS patients was 19 months with a prevalence of FAB M2 AML subtype.

In conclusion, our case highlights the importance of using X p-arm FISH probes to characterize abnormal karyotypes with structural abnormalities of the X chromosome. Furthermore, these results, together with the previously reported i(Xp) and Xq-, indicate that genetic imbalance resulting haploinsufficiency of genes located on the long arm of the X chromosome could drive neoplastic transformation. Of note, the prevalence in females, aged between 46 and 65 years, the myeloid phenotype, and the poor prognosis of all these cases indicate the need for specific molecular biology studies to better characterize the genetic lesions on the X chromosome, and the putative genes involved in the leukemic evolution.

Acknowledgements

The authors would like to acknowledge research funding from Associazione Italiana Ricerca sul Cancro (A.I.R.C, IG 16952 to MTV and 5916 to FLC).

References

1 

Mertens F, Johansson B and Mitelman F: Isochromosomes in neoplasia. Genes Chromosom. Cancer. 10:221–230. 1994.

2 

Adeyinka A, Smoley S, Fink S, Sanchez J, Van Dyke DL and Dewald G: Isochromosome (X)(p10) in hematologic disorders: FISH study of 14 new cases show three types of centromere signal patterns. Cancer Genet Cytogenet. 179:25–30. 2007. View Article : Google Scholar : PubMed/NCBI

3 

Mitelman F, Johansson B and Mertens F: Mitelman database of chromosome aberration and gene fusions in cancer. https://cgap.nci.nih.gov/Chromosomes/MitelmanApril 15–2017

4 

Gindina T: i(X)(p10) in female patients. Atlas genes Cytogenet Oncol Haematol. http://AtlasGeneticsOncology.org/Anomlies/iXp10FemaleID1500.htmlApril 15–2017

5 

Werner-Favre C, Beris P and Engel E: X chromosome rearrangements and leukemia. Cytogenet Cell Genet. 39:801985. View Article : Google Scholar : PubMed/NCBI

6 

Wolff DJ, Miller AP, Van Dyke DL, Schwartz S and Willard HF: Molecular definition of breakpoints associated with human Xq isochromosomes: Implications for mechanisms of formation. Am J Hum Genet. 58:154–160. 1996.PubMed/NCBI

7 

Wong KF, Siu LL and So CC: Deletion of Xq23 is a recurrent karyotypic abnormality in acute myeloid leukemia. Cancer Genet Cytogenet. 122:33–36. 2000. View Article : Google Scholar : PubMed/NCBI

8 

Olshanskaya YV, Udovichenko AI, Vodinskaya LA, Glasko EN, Parovitchnikova EN, Lorie YY, Dvirnik VN, Savchenko VG and Domracheva EV: Myelodysplastic syndromes with isolated deletion of the long arm of the chromosome X as a sole cytogenetic change. Cancer Genet Cytogenet. 167:47–50. 2006. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Gurnari C, Panetta P, Fabiani E, Nardone A, Postorivo D, Falconi G, Franceschini L, Rizzo M, Rapisarda V, De Bellis E, De Bellis E, et al: Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia. Mol Clin Oncol 8: 463-465, 2018.
APA
Gurnari, C., Panetta, P., Fabiani, E., Nardone, A., Postorivo, D., Falconi, G. ... Voso, M. (2018). Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia. Molecular and Clinical Oncology, 8, 463-465. https://doi.org/10.3892/mco.2017.1543
MLA
Gurnari, C., Panetta, P., Fabiani, E., Nardone, A., Postorivo, D., Falconi, G., Franceschini, L., Rizzo, M., Rapisarda, V., De Bellis, E., Lo‑Coco, F., Voso, M."Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia". Molecular and Clinical Oncology 8.3 (2018): 463-465.
Chicago
Gurnari, C., Panetta, P., Fabiani, E., Nardone, A., Postorivo, D., Falconi, G., Franceschini, L., Rizzo, M., Rapisarda, V., De Bellis, E., Lo‑Coco, F., Voso, M."Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia". Molecular and Clinical Oncology 8, no. 3 (2018): 463-465. https://doi.org/10.3892/mco.2017.1543
Copy and paste a formatted citation
x
Spandidos Publications style
Gurnari C, Panetta P, Fabiani E, Nardone A, Postorivo D, Falconi G, Franceschini L, Rizzo M, Rapisarda V, De Bellis E, De Bellis E, et al: Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia. Mol Clin Oncol 8: 463-465, 2018.
APA
Gurnari, C., Panetta, P., Fabiani, E., Nardone, A., Postorivo, D., Falconi, G. ... Voso, M. (2018). Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia. Molecular and Clinical Oncology, 8, 463-465. https://doi.org/10.3892/mco.2017.1543
MLA
Gurnari, C., Panetta, P., Fabiani, E., Nardone, A., Postorivo, D., Falconi, G., Franceschini, L., Rizzo, M., Rapisarda, V., De Bellis, E., Lo‑Coco, F., Voso, M."Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia". Molecular and Clinical Oncology 8.3 (2018): 463-465.
Chicago
Gurnari, C., Panetta, P., Fabiani, E., Nardone, A., Postorivo, D., Falconi, G., Franceschini, L., Rizzo, M., Rapisarda, V., De Bellis, E., Lo‑Coco, F., Voso, M."Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia". Molecular and Clinical Oncology 8, no. 3 (2018): 463-465. https://doi.org/10.3892/mco.2017.1543
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team